18F-FDG PET/CT与全身MRI在非小细胞肺癌M分期中的诊断效能:系统评价与Meta分析
该系统评价与Meta分析纳入4项研究共564例患者、559个病灶(其中233个转移灶),比较18F-FDG PET/CT、全身MRI和全身弥散加权成像对非小细胞肺癌转移灶的诊断效能。结果显示全身MRI和弥散加权成像与PET/CT的诊断比值比无统计学差异,作者认为两者是无辐射的替代选择。
要点
- 全身MRI汇总敏感度0.92、特异度0.93,对非小细胞肺癌转移灶诊断准确性高。
- PET/CT汇总敏感度0.83、特异度0.93;全身弥散加权成像汇总敏感度0.78、特异度0.91。
- 全身MRI与弥散加权成像的诊断比值比与PET/CT相比无统计学差异(p=0.186;p=0.638)。
诊断标准与关键数值
- 18F-FDG PET/CT汇总敏感度0.83(95%CI 0.54-0.95)、汇总特异度0.93(95%CI 0.87-0.96)。
- 全身MRI汇总敏感度0.92(95%CI 0.18-1.00)、汇总特异度0.93(95%CI 0.85-0.95)。
- 全身弥散加权成像汇总敏感度0.78(95%CI 0.46-0.93)、汇总特异度0.91(95%CI 0.79-0.96)。
- 全身弥散加权成像与PET/CT的诊断比值比无统计学差异(p=0.186),全身MRI与PET/CT亦无统计学差异(p=0.638)。
临床应用与阅片要点
- 作者认为全身MRI和弥散加权成像可作为无创、无辐射的替代选择用于非小细胞肺癌M分期,诊断效能与PET/CT相似。
- 全身MRI(联合或不联合弥散加权成像)对非小细胞肺癌转移灶的诊断评估具有高准确性。
局限性
- 全身MRI汇总敏感度的95%CI为0.18-1.00,置信区间宽。
- 全身弥散加权成像汇总敏感度的95%CI为0.46-0.93,置信区间宽。
- 全身弥散加权成像与PET/CT诊断比值比比较的p=0.186,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the diagnostic test accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), whole-body magnetic resonance imaging (WB-MRI), and whole-body diffusion-weighted imaging (WB-DWI) for the detection of metastases in patients with non-small cell lung cancer (NSCLC).
METHODS: MEDLINE, Embase, and Cochrane Library databases were searched up to June 2019. Studies were selected if they reported data that could be used to construct contingency tables to compare 18F-FDG PET/CT, WB-MRI, and WB-DWI. Two authors independently extracted data on study characteristics and assessed methodological quality using the Quality Assessment of Diagnostic Accuracy Studies. Forest plots were generated for sensitivity and specificity of 18F-FDG PET/CT, WB-MRI, and whole-body diffusion-weighted imaging (WB-DWI). Summary receiver operating characteristic plots were created.
RESULTS: The 4 studies meeting inclusion criteria had a total of 564 patients and 559 lesions, 233 of which were metastases. In studies of 18F-FDG PET/CT, the pooled estimates of sensitivity and specificity were 0.83 (95% confidence interval [CI], 0.54-0.95) and 0.93 (95% CI, 0.87-0.96), respectively. For WB-MRI, pooled sensitivity was 0.92 (95% CI, 0.18-1.00) and pooled specificity was 0.93 (95% CI, 0.85-0.95). Pooled sensitivity and specificity for WB-DWI were 0.78 (95% CI, 0.46-0.93) and 0.91 (95% CI, 0.79-0.96), respectively. There was no statistical difference between the diagnostic odds ratio of WB-MRI and WB-DWI compared with that of PET/CT (p = 0.186 for WB-DWI; p = 0.638 for WB-MRI).
CONCLUSION: WB-MRI and DWI are radiation-free alternatives with comparable diagnostic performance to 18F-FDG PET/CT for M staging of NSCLC.
KEY POINTS: • Whole-body MRI with or without diffusion-weighted imaging has a high accuracy for the diagnostic evaluation of metastases in patients with non-small cell lung cancer. • Whole-body MRI may be used as a non-invasive and radiation-free alternative to positron emission tomography with CT with similar diagnostic performance.
引用
- Machado Medeiros T, Altmayer S, Watte G, et al. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Eur Radiol. 2020. PMID: 32125513. doi:10.1007/s00330-020-06703-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。